Figure 2. Patient Survival.
Progression-free survival among 9 patients with PDL1 amplification treated with checkpoint blockade (median, 15.2 months; range, 1.2 to ≥24.1 months). Median overall survival among patients with PDL1 amplification was not reached from start of checkpoint blockade (range, 1.6 to ≥24.1 months). NA indicates not applicable.